Citius Pharmaceuticals, Inc. 8K

Citius Oncology reported strong early commercial uptake and expanding clinical development for its newly launched CTCL therapy LYMPHIR, supported by broad payer coverage and growing institutional adoption.

On March 31, 2026, Citius Oncology, Inc. announced a commercial update on the U.S. launch of LYMPHIR (denileukin diftitox-cxdl) for relapsed or refractory cutaneous T-cell lymphoma, reporting strong early institutional adoption, broad and expanding payer coverage, no reported reimbursement denials, and initial penetration into community infusion centers, while also highlighting adequate commercial supply, ongoing international distribution arrangements in Europe and the Middle East, and expansion of clinical development through investigator-sponsored and Phase I studies evaluating LYMPHIR in combination and pre-CAR-T settings for broader oncology indications.

Filing Facts

CIK

1506251

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-037524

Alert Tier

6